甲胺,与年龄相关的认知衰退,以及大脑病理
Ajay Sood1, Ana Werneck Capuano1, Robert Smith Wilson1
1Rush Alzheimer's Disease Center, Chicago, IL, USA.
Neurobiology of aging
|November 6, 2023
概括
在8年的时间里,甲胺使用与较慢的认知衰退有关,特别是在情节性和语义性记忆中. 然而,它没有显著影响阿尔茨海默病的病理学或整体心脏病发作在脑尸检研究.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 认知衰退和神经退行性疾病对公众健康构成重大挑战.
- 甲胺是一种广泛用于治疗2型糖尿病的药物.
- 了解甲胺对认知功能和大脑健康的长期影响至关重要.
研究的目的:
- 调查甲福明使用与随时间推移的认知变化之间的关联.
- 检查甲胺与特定的大脑病理,包括阿尔茨海默氏症标志物和心脏病发作之间的关系.
- 评估甲胺对全球认知,情节性记忆和语义记忆等认知领域的影响.
主要方法:
- 纵向研究设计,平均随访时间为8年.
- 线性混合效应模型根据年龄,性别和教育情况进行调整,以评估认知衰退.
- 对尸检数据的分析,以评估阿尔茨海默病的病理学和心脏病发作.
- 敏感性分析包括所有糖尿病药物使用.
主要成果:
- 与非使用者相比,甲胺使用者在全球认知得分下降的速度明显较慢 (p=0.027).
- 特定的认知领域,包括情节性和语义性记忆,在甲福明使用者中显示下降的速度较慢.
- 在尸检样本中,在甲福林使用者和非使用者之间没有观察到阿尔茨海默病病理或心脏病发作的重大差异.
- 甲胺使用者患上皮下心脏病发作的几率较高,但动脉样硬化和动脉样硬化的几率较低.
结论:
- 甲福明的使用可能与对认知能力下降的保护作用有关,特别是在与记忆相关的功能中.
- 观察到的甲福明的认知益处似乎与阿尔茨海默病的病理学减少或整体心脏病发作的负担没有直接联系.
- 需要进行进一步的研究,以阐明甲胺潜在的神经保护作用和它对脑血管健康的特定影响背后的机制.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Cognitive Development During Adulthood
122
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
122
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
130
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
130
Aging
59
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
59
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197


